BioSpace News Archive

Atea Pharmaceuticals, Inc. today announced that it will host a live conference call and audio webcast on Wednesday, February 28, 2024, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023, and to provide a business update.

Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the publication of preclinical data in Molecular Therapy that further validates the therapeutic potential of ADX-097, a tissue-targeted complement inhibitor.

Armata Pharmaceuticals, Inc. today announced that Mina Pastagia , M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston.

Lutris Pharma today announced the publication of data from its phase 1/2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for the treatment of radiation-induced dermatitis (RD) in patients with breast cancer.

Prior to launching the Long COVID clinical trial, Tevogen seeks to address whether Long COVID occurs more commonly with certain HLA types and less commonly with others, or whether Long COVID occurs randomly in the population regardless of HLA.

Otolith Labs, a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, appointed Dan Wagner as Chief Commercial Officer and Raphael Michel as an independent Board member.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the fourth quarter and full year of fiscal year 2023, ended November 30, 2023.

The sea lamprey, a 500-million-year-old animal with a sharp-toothed suction cup for a mouth, is the thing of nightmares.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.